相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
Fernanda Palhano-Fontes et al.
PSYCHOLOGICAL MEDICINE (2019)
Cessation and reduction in alcohol consumption and misuse after psychedelic use
Albert Garcia-Romeu et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2019)
Effects of the synthetic psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) on ethanol consumption and place conditioning in male mice
Aboagyewaah Oppong-Damoah et al.
PSYCHOPHARMACOLOGY (2019)
Changes in the prevalence and correlates of cocaine use and cocaine use disorder in the United States, 2001-2002 and 2012-2013
Bradley T. Kerridge et al.
ADDICTIVE BEHAVIORS (2019)
Modulation of Serum Brain-Derived Neurotrophic Factor by a Single Dose of Ayahuasca: Observation From a Randomized Controlled Trial
Raissa Nobrega de Almeida et al.
FRONTIERS IN PSYCHOLOGY (2019)
The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal
Christina A. Brezing et al.
NEUROPSYCHOPHARMACOLOGY (2018)
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
R. L. Carhart-Harris et al.
PSYCHOPHARMACOLOGY (2018)
The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption
Alan K. Davis et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2018)
The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act
Matthew W. Johnson et al.
NEUROPHARMACOLOGY (2018)
Psychedelics Promote Structural and Functional Neural Plasticity
Calvin Ly et al.
CELL REPORTS (2018)
Ayahuasca and Its DMT- and β-carbolines - Containing Ingredients Block the Expression of Ethanol-Induced Conditioned Place Preference in Mice: Role of the Treatment Environment
Elisangela G. Cata-Preta et al.
FRONTIERS IN PHARMACOLOGY (2018)
Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants - United States, 2015-2016
Puja Seth et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2018)
Cortisol Modulation by Ayahuasca in Patients With Treatment Resistant Depression and Healthy Controls
Ana C. de Menezes Galvao et al.
FRONTIERS IN PSYCHIATRY (2018)
Trends in use of prescription stimulants in the United States and Territories, 2006 to 2016
Brian J. Piper et al.
PLOS ONE (2018)
Psychedelics as anti-inflammatory agents
Thomas W. Flanagan et al.
INTERNATIONAL REVIEW OF PSYCHIATRY (2018)
Alterations of consciousness and mystical-type experiences after acute LSD in humans
Matthias E. Liechti et al.
PSYCHOPHARMACOLOGY (2017)
Long-term follow-up of psilocybin-facilitated smoking cessation
Matthew W. Johnson et al.
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE (2017)
A single administration of the hallucinogen, 4-acetoxy-dimethyltryptamine, prevents the shift to a drug-dependent state and the expression of withdrawal aversions in rodents
Hector Vargas-Perez et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2017)
National Trends in and Correlates of Nonmedical Use of Prescription Stimulants, Nonmedical Use Frequency, and Use Disorders
Beth Han et al.
JOURNAL OF CLINICAL PSYCHIATRY (2017)
The association of psychedelic use and opioid use disorders among illicit users in the United States
Vincent D. Pisano et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2017)
An online survey of tobacco smoking cessation associated with naturalistic psychedelic use
Matthew W. Johnson et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2017)
Changes in US Lifetime Heroin Use and Heroin Use Disorder Prevalence From the 2001-2002 to 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions
Silvia S. Martins et al.
JAMA PSYCHIATRY (2017)
US Adult Illicit Cannabis Use, Cannabis Use Disorder, and Medical Marijuana Laws 1991-1992 to 2012-2013
Deborah S. Hasin et al.
JAMA PSYCHIATRY (2017)
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
Robin L. Carhart-Harris et al.
SCIENTIFIC REPORTS (2017)
Trends and correlates of cocaine use and cocaine use disorder in the United States from 2011 to 2015
William S. John et al.
DRUG AND ALCOHOL DEPENDENCE (2017)
Prescription Opioid Use, Misuse, and Use Disorders in US Adults: 2015 National Survey on Drug Use and Health
Beth Han et al.
ANNALS OF INTERNAL MEDICINE (2017)
Trends in older adult nonmedical prescription drug use prevalence: Results from the 2002-2003 and 2012-2013 National Survey on Drug Use and Health
Ty S. Schepis et al.
ADDICTIVE BEHAVIORS (2016)
Increases in Drug and Opioid Overdose DeathsUnited States, 2000-2014
R. A. Rudd et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2016)
Association Between Cannabis and Psychosis: Epidemiologic Evidence
Suzanne H. Gage et al.
BIOLOGICAL PSYCHIATRY (2016)
Trends and Correlates of Cannabis-involved Emergency Department Visits: 2004 to 2011
He Zhu et al.
JOURNAL OF ADDICTION MEDICINE (2016)
Nonmedical Prescription Opioid Use and DSM-5 Nonmedical Prescription Opioid Use Disorder in the United States
Tulshi D. Saha et al.
JOURNAL OF CLINICAL PSYCHIATRY (2016)
Prescriptions, Nonmedical Use, and Emergency Department Visits Involving Prescription Stimulants
Lian-Yu Chen et al.
JOURNAL OF CLINICAL PSYCHIATRY (2016)
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Roland R. Griffiths et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
Stephen Ross et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Classic hallucinogens in the treatment of addictions
Michael P. Bogenschutz et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2016)
Recent Trends in the Prevalence of Marijuana Use and Associated Disorders in the United States
Richard A. Grucza et al.
JAMA PSYCHIATRY (2016)
Epidemiology of DSM-5 Drug Use Disorder Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III
Bridget F. Grant et al.
JAMA PSYCHIATRY (2016)
Psychosocial interventions for cannabis use disorder
Peter J. Gates et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2016)
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Robin L. Carhart-Harris et al.
LANCET PSYCHIATRY (2016)
National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment
Christopher M. Jones et al.
AMERICAN JOURNAL OF PUBLIC HEALTH (2015)
Past 15-year trends in adolescent marijuana use: Differences by race/ethnicity and sex
Renee M. Johnson et al.
DRUG AND ALCOHOL DEPENDENCE (2015)
Changes in Substance Abuse Treatment Use Among Individuals With Opioid Use Disorders in the United States. 2004-2013
Brendan Saloner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Frederick S. Barrett et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
Tomislav Majic et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Michael P. Bogenschutz et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
Medication-Assisted Treatment of Opioid Use Disorder: Review of the Evidence and Future Directions
Hilary Smith Connery
HARVARD REVIEW OF PSYCHIATRY (2015)
Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013
Deborah S. Hasin et al.
JAMA PSYCHIATRY (2015)
Hidden Populations, Online Purposive Sampling, and External Validity: Taking off the Blindfold
Monica J. Barratt et al.
FIELD METHODS (2015)
Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases
Peter Gasser et al.
JOURNAL OF NERVOUS AND MENTAL DISEASE (2014)
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
Matthew W. Johnson et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2014)
Medication-Assisted Therapies - Tackling the Opioid-Overdose Epidemic
Nora D. Volkow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Indigenous Supports for Recovery from Alcoholism and Drug Abuse: The Native American Church
Bob Prue
JOURNAL OF ETHNIC & CULTURAL DIVERSITY IN SOCIAL WORK (2013)
Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses
Michael P. Bogenschutz et al.
DRUG TESTING AND ANALYSIS (2012)
Health status of ayahuasca users
Paulo Cesar Ribeiro Barbosa et al.
DRUG TESTING AND ANALYSIS (2012)
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Teri S. Krebs et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2012)
Extent of illicit drug use and dependence, and their contribution to the global burden of disease
Louisa Degenhardt et al.
LANCET (2012)
Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin
Katherine A. MacLean et al.
JOURNAL FOR THE SCIENTIFIC STUDY OF RELIGION (2012)
Serotonergic Hallucinogens and Emerging Targets for Addiction Pharmacotherapies
Stephen Ross
PSYCHIATRIC CLINICS OF NORTH AMERICA (2012)
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Charles S. Grob et al.
ARCHIVES OF GENERAL PSYCHIATRY (2011)
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness
Katherine A. MacLean et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Roland R. Griffiths et al.
PSYCHOPHARMACOLOGY (2011)
Assessment of addiction severity among ritual users of ayahuasca
Josep Maria Fabregas et al.
DRUG AND ALCOHOL DEPENDENCE (2010)
Delay Discounting in Current and Former Marijuana-Dependent Individuals
Matthew W. Johnson et al.
EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY (2010)
Contingency management: Utility in the treatment of drug abuse disorders
M. L. Stitzer et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Human hallucinogen research: guidelines for safety
M. W. Johnson et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2008)
Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later
R. R. Griffiths et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2008)
Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders
W. P. Knapp et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2007)
Contingency management for treatment of substance use disorders: a meta-analysis
Michael Prendergast et al.
ADDICTION (2006)
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
R. R. Griffiths et al.
PSYCHOPHARMACOLOGY (2006)
Screening for hazardous or harmful drinking using one or two quantity-frequency questions
A Canagasaby et al.
ALCOHOL AND ALCOHOLISM (2005)
Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample
AH Berman et al.
EUROPEAN ADDICTION RESEARCH (2005)
The external validity of results derived from ecstasy users recruited using purposive sampling strategies
L Topp et al.
DRUG AND ALCOHOL DEPENDENCE (2004)
Hallucinogen persisting perception disorder: what do we know after 50 years?
JH Halpern et al.
DRUG AND ALCOHOL DEPENDENCE (2003)
Hallucinogens and redemption
MD de Rios et al.
JOURNAL OF PSYCHOACTIVE DRUGS (2002)
A national 5-year follow-up of treatment outcomes for cocaine dependence
DD Simpson et al.
ARCHIVES OF GENERAL PSYCHIATRY (2002)
分享论文
